HBPCF (Helix BioPharma) Cash And Cash Equivalents : $1.39 Mil (As of Jan. 2025)

View and export this data going back to 2008. Start your Free Trial

What is Helix BioPharma Cash And Cash Equivalents?

Helix BioPharma's quarterly cash and cash equivalents declined from Jul. 2024 ($0.79 Mil) to Oct. 2024 ($0.17 Mil) but then increased from Oct. 2024 ($0.17 Mil) to Jan. 2025 ($1.39 Mil).

Helix BioPharma's annual cash and cash equivalents declined from Jul. 2022 ($2.51 Mil) to Jul. 2023 ($0.61 Mil) but then increased from Jul. 2023 ($0.61 Mil) to Jul. 2024 ($0.79 Mil).

Helix BioPharma Cash And Cash Equivalents Historical Data

The historical data trend for Helix BioPharma's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Helix BioPharma Cash And Cash Equivalents Chart

Helix BioPharma Annual Data

Trend

Jul15

Jul16

Jul17

Jul18

Jul19

Jul20

Jul21

Jul22

Jul23

Jul24

Cash And Cash Equivalents

Get a 7-Day Free Trial

3.14

2.85

2.51

0.61

0.79

Helix BioPharma Quarterly Data
	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24	Apr24	Jul24	Oct24	Jan25
Cash And Cash Equivalents	Get a 7-Day Free Trial															0.09	0.52	0.79	0.17	1.39

Helix BioPharma Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Helix BioPharma (OTCPK:HBPCF) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Helix BioPharma Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Helix BioPharma's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Helix BioPharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Helix BioPharma Corp (OTCPK:HBPCF) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

HBP0:Germany HBP:Canada

Address

40 Temperance Street, Suite 2700, Bay Adelaide Centre - North Tower, Toronto, ON, CAN, M5H0B4

Website

https://www.helixbiopharma.com

Helix BioPharma Corp is a clinical-stage biopharmaceutical company. It is focused on cancer drug development. The company develops therapies in the field of immuno-oncology based on its proprietary technology mainly in the areas of cancer prevention and treatment. Its pipeline candidate is L-DOS47 for Tumor Defence Breaker is in clinical trials for pancreatic cancer.